Just a moment...
Press 'Enter' to add multiple search terms. Rules for Better Search
Use comma for multiple locations.
---------------- For section wise search only -----------------
Accuracy Level ~ 90%
Press 'Enter' after typing page number.
Press 'Enter' after typing page number.
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
Press 'Enter' after typing page number.
Press 'Enter' after typing page number.
Don't have an account? Register Here
Press 'Enter' after typing page number.
Issues: Whether the writ petition challenging the show-cause notice and seeking a declaration that the petitioner's product was not covered by Schedule-B of the Narcotics Drugs and Psychotropic Substances (Regulation of Controlled Substances) Order, 2013 could be entertained in view of the need for factual inquiry and the rule of exhaustion of alternate remedies.
Analysis: The question whether the petitioner's product fell within Schedule-B under the 2013 Order depended on factual examination of the product's composition and the nature of MEK in the product. The Court found that the rival contentions raised arguable issues that could not be finally resolved at the stage of a challenge to the show-cause notice. Since the 2013 Order was made under Section 9-A of the NDPS Act, and Clause 10 regulates export of Schedule-B controlled substances through the Narcotics Commissioner's NOC process, the dispute required the petitioner to respond before the statutory authority. No exceptional circumstance was made out to depart from the settled rule that writ jurisdiction should not ordinarily be used to short-circuit a pending adjudicatory process, particularly when the alleged lack of jurisdiction was not absolutely apparent on the face of the record.
Conclusion: The writ petition was not maintainable at this stage and the petitioner was relegated to the statutory remedy of replying to the show-cause notice and facing the adjudication proceedings.